Background The RSV prevention, Beyfortus (nirsevimab) which is a monoclonal antibody, was approved by the FDA on July 17, 2023. The CDC and ACIP provided recommendations which were published in the MMWR on August 25, 2023. The FDA accelerated approval of Beyfortus since the RSV prevention was categorized as “Breakthrough Therapy Designation”. Note that Beyfortus…
As pediatric practice owners, providing the best care for your young patients is a top priority. This includes ensuring access to vaccines to protect children from preventable diseases. The cost of vaccines steadily increases each and every year. To navigate these challenges and maintain the highest level of care for your patients, it’s crucial to…
The Pfizer COVID-19 vaccine was approved by the FDA for use in children 5-11 years. Since about 1 out of 4 new COVID-19 cases are for children under the age of 18 and the previous age indication was 12 years and older, this is a very important event in the next stage of preventing…
The two primary vaccines to prevent COVID-19 given in the US are the mra vaccines developed/marketed by Moderna and Pfizer. The rapid immunization rates leveraging these vaccines has been a critical component of fighting the COVID-19 Pandemic. This week, the Pfizer COVID-19 vaccine was approved by the FDA for use in children 12 years…
Early Monday morning, November 9th, Pfizer announced some positive results regarding their COVID-19 Vaccine they are developing with BioNTech. This vaccine candidate is a two-dose series. The phase III clinical trials involved over 40,000 patients. There is some data in the press release that based on exposing patients who received the vaccine to…
Login